NV-BITSENSING
12.1.2021 13:02:35 CET | Business Wire | Press release
bitsensing , a South Korean radar technology startup, introduces the new mini Healthcare Radar, mini-H , the smallest high-resolution 60GHz IoT Radar sensor in the lineup. The innovation behind the mini-H demonstrates the company’s industry leading expertise in designing and building cutting edge radar technology that can transform healthcare, automotive, mobility, smart home, security, and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005325/en/
Dr. Jae-Eun Lee, CEO of bitsensing, a seasoned engineer in radar technology and formerly a part of the automotive world at Mando Corp., knows what it takes to create a safe and conveniently connected world. “Revolutionary technologies such as mini-H are propelling what is possible in all facets of our daily lives,” says Lee. “We at bitsensing are committed to integrating these groundbreaking radar technologies to help build smart lives and smart cities which ultimately elevates the quality of life for all.”
The advanced mini-H sensor attaches to the wall and can detect, in real-time, presence, movement, breathing or lack thereof, and falls by measuring breathing patterns and pulsating vessels without the use of intrusive cameras or wearables.
Specifically designed for a more intelligent and safer monitoring system for telehealth, mini-H can be used in dark or wet places and works regardless of clothes or blankets. The Bluetooth and WiFi communication module allows for a seamless transfer of data from the radar to dashboards or the app for easy tracking. This fully wireless product makes it quick and easy to implement software advancements, ensuring the product is always up to date. The sleek, compact aesthetic of the product also allows for an easy integration while the plug and play style provides instant monitoring of activities with the option to adjust settings for optimal personalization.
As a leading radar solution company, bitsensing offers complete end to end services, creating customizable radars like the mini-H that exceed industry standards in convenience and security. The nimble structure of bitsensing allows the team to deliver powerful products quickly while working directly with end customers across a large range of industries to ensure satisfaction and broaden their horizons of what is possible in a smart life.
CES attendees can visit bitsensing’s virtual booth to learn more about the mini-H from January 11-14, 2021. To view the mini-H informational product video, please visit here . If you are interested in learning more about our radar solution offerings, please visit www.bitsensing.com .
mini-H Product Specifications
Specs subject to change without notice. All functionality, features, specifications and other product information provided in this document including, but not limited to, the benefits, design, pricing, components, performance, availability, and capabilities of the product are subject to change without notice.
General Spec |
|
Centered Frequency |
61 GHz |
Bandwidth |
3.75 GHz |
Communication Interface |
WiFi or Bluetooth, RS485 |
Coverage Spec |
|
Detection Range |
0.2m ~ 2.5m |
Field of View |
±60° (Azimuth), ±60° (Elevation) |
Feature |
Moving, Falling, Presence, Apnea |
Vital Sign |
Respiration* |
Resolution |
0.04m |
Electrical Spec |
|
Operating Voltage |
7V ~ 14V |
Current Consumption |
Max 3W |
Mechanical Spec |
|
Dimensions |
50 x 50 x 15 mm |
Weight |
100g** |
Connector |
Open terminal Cable |
Environment Spec |
|
Operating Temperature |
-20 ~ +85 °C |
* The data driven by respiration detection may be limited and is designed to be used for apnea detection |
** The weight is without cable |
About bitsensing
bitsensing is an imaging radar technology company committed to building safer smart cities and elevating connected living by designing cutting-edge sensor fusions and AI solutions bringing an unprecedented level of intelligence to smart living. Founded in 2018 by seasoned automotive experts, bitsensing is one of the only startups delivering optimal technologies that meet and exceed the high level of safety and convenience that the industry demands. bitsensing is transforming possibilities to bring democratization of smart life in healthcare, automotive, mobility, smart home, security, and beyond.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom